N Zaveri

Summary

Affiliation: SRI International
Country: USA

Publications

  1. ncbi Steroidal oxathiazine inhibitors of estrone sulfatase
    Richard H Peters
    SRI International, Life Science Division, 333 Ravenswood Avenue Bldg, 100 2, Menlo Park, CA 94025, USA
    Steroids 68:97-110. 2003
  2. ncbi Synthesis of a 3,4,5-trimethoxybenzoyl ester analogue of epigallocatechin-3-gallate (EGCG): a potential route to the natural product green tea catechin, EGCG
    N T Zaveri
    Pharmaceutical Discovery Division, SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, USA
    Org Lett 3:843-6. 2001
  3. ncbi Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
    N Zaveri
    Pharmaceutical Discovery Division, SRI International, Menlo Park, CA 94025, USA
    Eur J Pharmacol 428:29-36. 2001
  4. ncbi Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents
    Nurulain Zaveri
    Biosciences Division, Drug Discovery, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA
    Life Sci 73:663-78. 2003
  5. ncbi A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor
    Nurulain T Zaveri
    Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA
    J Med Chem 47:2973-6. 2004
  6. ncbi Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications
    Nurulain T Zaveri
    Drug Discovery Program, Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    Life Sci 78:2073-80. 2006
  7. ncbi Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP
    Nurulain Zaveri
    Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    AAPS J 7:E345-52. 2005
  8. ncbi SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice
    Taline V Khroyan
    Center for Health Sciences, SRI International, Menlo Park, CA 94025, USA
    J Pharmacol Exp Ther 320:934-43. 2007
  9. ncbi A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer
    Louise M Rasmussen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark
    Breast Cancer Res Treat 106:191-203. 2007
  10. ncbi Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells
    Nahid S Waleh
    Drug Discovery Program, Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    Anticancer Res 25:397-402. 2005

Collaborators

Detail Information

Publications10

  1. ncbi Steroidal oxathiazine inhibitors of estrone sulfatase
    Richard H Peters
    SRI International, Life Science Division, 333 Ravenswood Avenue Bldg, 100 2, Menlo Park, CA 94025, USA
    Steroids 68:97-110. 2003
    ..The synthesis and biological activity of a number of these unique steroidal ESIs are described...
  2. ncbi Synthesis of a 3,4,5-trimethoxybenzoyl ester analogue of epigallocatechin-3-gallate (EGCG): a potential route to the natural product green tea catechin, EGCG
    N T Zaveri
    Pharmaceutical Discovery Division, SRI International, 333 Ravenswood Avenue, Menlo Park, California 94025, USA
    Org Lett 3:843-6. 2001
    ..This synthesis provides a possible route to the polyphenolic green tea natural product EGCG...
  3. ncbi Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
    N Zaveri
    Pharmaceutical Discovery Division, SRI International, Menlo Park, CA 94025, USA
    Eur J Pharmacol 428:29-36. 2001
    ..Our results indicate that opiates and neuroleptics may be good starting points for ORL1 receptor ligand design, and the selectivity may be modulated by appropriate structural modifications...
  4. ncbi Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents
    Nurulain Zaveri
    Biosciences Division, Drug Discovery, SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA
    Life Sci 73:663-78. 2003
    ..This review presents an overview of the various peptide and nonpeptide ORL1 ligands with an emphasis on their potential therapeutic utility in various human disorders...
  5. ncbi A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor
    Nurulain T Zaveri
    Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA
    J Med Chem 47:2973-6. 2004
    ..The SAR revealed in this new series will provide important insights for the development of pharmacophores for agonist and antagonist actions at the NOP receptor...
  6. ncbi Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications
    Nurulain T Zaveri
    Drug Discovery Program, Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    Life Sci 78:2073-80. 2006
    ....
  7. ncbi Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP
    Nurulain Zaveri
    Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    AAPS J 7:E345-52. 2005
    ....
  8. ncbi SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice
    Taline V Khroyan
    Center for Health Sciences, SRI International, Menlo Park, CA 94025, USA
    J Pharmacol Exp Ther 320:934-43. 2007
    ..In summary, the mixed NOP/mu-opioid partial agonist SR 16435 exhibited both NOP and mu-opioid receptor-mediated behaviors...
  9. ncbi A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer
    Louise M Rasmussen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark
    Breast Cancer Res Treat 106:191-203. 2007
    ..Thus, the dual-target SR 16157 is possibly a promising new treatment alternative, superior to tamoxifen...
  10. ncbi Novel D-ring analog of epigallocatechin-3-gallate inhibits tumor growth and VEGF expression in breast carcinoma cells
    Nahid S Waleh
    Drug Discovery Program, Biosciences Division, SRI International, Menlo Park, CA 94025, USA
    Anticancer Res 25:397-402. 2005
    ..Such synthetic analogs are valuable for understanding the structure-function relationship of EGCG and identifying relevant mechanisms of the chemopreventive action of EGCG...